How to Discuss a Healthcare Deal: Beyond the Press Release

Introduction

"What deal are you following?" is the most revealing question in a healthcare IB interview. It is not a factual recall test. It is a diagnostic tool that tells the interviewer whether you think like a banker or like someone who reads press releases. The difference between these two modes is the difference between a first-round pass and a first-round rejection.

The strongest deal discussions follow a four-layer structure, with each layer demonstrating a different analytical competency.

Layer 1: Facts (30 seconds)

State the buyer, target, deal value, structure (cash, stock, or combination), and timing. This is table stakes. Getting the facts wrong (wrong price, wrong buyer, wrong year) is immediately disqualifying. Getting the facts right earns no credit because everyone who prepared at all can cite these.

Layer 2: Strategic Rationale (60-90 seconds)

This is where you differentiate. Explain why the buyer needed this specific target at this specific time. The strategic rationale should connect to a structural industry dynamic, not just "they wanted to grow."

Strategic Rationale Analysis

The process of identifying the buyer-specific motivations that made a particular transaction necessary at a particular time. In healthcare M&A, strategic rationale typically connects to one or more structural forces: patent cliff urgency (revenue replacement), GLP-1 positioning (market entry or expansion), platform acquisition (technology, not just product), PE roll-up economics (multiple arbitrage), or competitive defensive moves (preventing a rival from acquiring the target). A strong strategic rationale answer connects the deal to the buyer's specific situation, not generic industry trends.

For Pfizer/Seagen, the strategic rationale goes deeper than "Pfizer wanted oncology assets." Pfizer faced an acute revenue crisis: COVID franchise revenue was declining from a $37 billion peak, and the company needed a transformative platform to rebuild its growth trajectory. Seagen was not just a product portfolio acquisition; it was a technology platform acquisition. Seagen's proprietary ADC linker-payload technology and its four approved products (Adcetris, Padcev, Tukysa, Tivdak) provided both near-term revenue and a pipeline of next-generation candidates. Pfizer was buying the ability to generate multiple future ADC products, not just the current portfolio.

Layer 3: Valuation and Structure (30-60 seconds)

Discuss the implied valuation multiples and deal structure. Show that you can evaluate whether the price was reasonable relative to comparables and alternatives.

Also address the deal structure: why was it all-cash versus stock? (Pfizer had a strong balance sheet from COVID revenue and wanted to avoid diluting its shareholders.) Were there any CVRs or earnouts? (No, because Seagen had approved, revenue-generating products, reducing the need for contingent consideration.) What were the regulatory considerations? (The FTC reviewed the deal but cleared it, which was not guaranteed given the size and market overlap in oncology.)

Layer 4: Your Analytical View (30 seconds)

Close with a concise, defensible opinion about the deal. This is not about being right or wrong. It is about demonstrating that you can form an independent analytical view based on the evidence.

"I think this deal will ultimately prove to be value-creating for Pfizer, but the timeline is longer than the market expects. ADC integration is complex because the R&D talent and the technology platform need to be preserved, and Pfizer's track record with large acquisitions is mixed. The strategic logic is sound, but execution risk is the variable I would monitor."

Avoid picking the most obvious deal that every candidate will discuss unless you can add genuine depth that others will not have. If you pick Pfizer/Seagen, which is the most commonly cited healthcare deal, your analysis needs to be exceptionally detailed to stand out. A less well-known deal discussed with genuine analytical depth will impress more than a well-known deal discussed at the press-release level.

The next article covers how to discuss healthcare trends using the Informed View Framework, providing structure for the equally common "what trends are you following?" question.